Braeburn's Brixadi becomes new option for opioid use disorder

Opioid use disorder specialist Braeburn Pharmaceuticals (Nasdaq: BBRX) has achieved a major milestone with its lead product, Brixadi (buprenorphine).

The US Food and Drug Administration (FDA) has approved Brixadi extended-release injection for subcutaneous use, a weekly and monthly medication for moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with a transmucosal buprenorphine-containing product.

"Having a weekly and monthly option that provides buprenorphine over one week or one month could benefit patients, their loved ones and the treatment providers"Brixadi is the first and only weekly and monthly subcutaneous injection for moderate to severe opioid use disorder, and adds another option for patients impacted by addicted to dangerous opiates.